Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(11%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
11%
Ph early_phase_1
1
11%
Ph not_applicable
1
11%
Ph phase_4
4
44%

Phase Distribution

2

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
1(14.3%)
Phase 1Safety & dosage
1(14.3%)
Phase 4Post-market surveillance
4(57.1%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(1)
Other(7)

Detailed Status

unknown7
Active, not recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (14.3%)
Phase 11 (14.3%)
Phase 44 (57.1%)
N/A1 (14.3%)

Trials by Status

active_not_recruiting111%
completed111%
unknown778%

Recent Activity

1 active trials
Showing 5 of 9
active_not_recruitingphase_4

Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic HBV Infection

NCT05410496
completedphase_1

Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B

NCT04629976
unknownphase_4

Tenofovir Alafenamide for HBV Prophylaxis in Post Orthotopic Liver Transplant

NCT05063071
unknownphase_4

The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in China

NCT04997564
unknownnot_applicable

Tenofovir Alafenamide for HBV Prophylaxis in HBV(-) Liver Transplant Recipients With HBcAb+ Donors

NCT04703465
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05410496Phase 4

Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic HBV Infection

Active Not Recruiting
NCT04629976Phase 1

Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B

Completed
NCT05063071Phase 4

Tenofovir Alafenamide for HBV Prophylaxis in Post Orthotopic Liver Transplant

Unknown
NCT04997564Phase 4

The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in China

Unknown
NCT04703465Not Applicable

Tenofovir Alafenamide for HBV Prophylaxis in HBV(-) Liver Transplant Recipients With HBcAb+ Donors

Unknown
NCT04507607Early Phase 1

Efficacy and Safety of TAF in Pregnant Women With Chronic Hepatitis B Infection

Unknown
NCT04201808Phase 4

Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides

Unknown
NCT04237376

Chronic HBV Infection in Pregnant Women Taking TAF to Prevent Vertical Transmission

Unknown
NCT03566030

Switching From Tenofovir Disoproxi Fumarate to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Antiviral Resistance

Unknown

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9